Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series.
Publication
, Journal Article
James, OG; Linares, AR; Hellegers, C; Doraiswamy, PM; Wong, TZ
Published in: Clin Nucl Med
July 1, 2021
Early, accurate diagnosis of Alzheimer disease (AD) is essential but remains challenging. Neuropathological hallmarks of AD are β-amyloid neuritic plaques and tau protein neurofibrillary tangles. 18F-Florbetapir is one of several available PET tracers for imaging cortical fibrillary β-amyloid plaques. 18F-Flortaucipir PET was recently approved for evaluating the distribution and density of aggregated neurofibrillary tangles. We present cases of mild cognitive impairment or suspected AD to depict the nuances of flortaucipir distribution and scan interpretation as well as how combined information from amyloid and tau PET may help with differential diagnosis and prognosis.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Nucl Med
DOI
EISSN
1536-0229
Publication Date
July 1, 2021
Volume
46
Issue
7
Start / End Page
605 / 608
Location
United States
Related Subject Headings
- Positron-Emission Tomography
- Nuclear Medicine & Medical Imaging
- Middle Aged
- Male
- Humans
- Ethylene Glycols
- Cognitive Dysfunction
- Carbolines
- Biomarkers
- Aniline Compounds
Citation
APA
Chicago
ICMJE
MLA
NLM
James, O. G., Linares, A. R., Hellegers, C., Doraiswamy, P. M., & Wong, T. Z. (2021). Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series. Clin Nucl Med, 46(7), 605–608. https://doi.org/10.1097/RLU.0000000000003493
James, Olga G., Alexandra R. Linares, Caroline Hellegers, P Murali Doraiswamy, and Terence Z. Wong. “Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series.” Clin Nucl Med 46, no. 7 (July 1, 2021): 605–8. https://doi.org/10.1097/RLU.0000000000003493.
James OG, Linares AR, Hellegers C, Doraiswamy PM, Wong TZ. Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series. Clin Nucl Med. 2021 Jul 1;46(7):605–8.
James, Olga G., et al. “Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series.” Clin Nucl Med, vol. 46, no. 7, July 2021, pp. 605–08. Pubmed, doi:10.1097/RLU.0000000000003493.
James OG, Linares AR, Hellegers C, Doraiswamy PM, Wong TZ. Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series. Clin Nucl Med. 2021 Jul 1;46(7):605–608.
Published In
Clin Nucl Med
DOI
EISSN
1536-0229
Publication Date
July 1, 2021
Volume
46
Issue
7
Start / End Page
605 / 608
Location
United States
Related Subject Headings
- Positron-Emission Tomography
- Nuclear Medicine & Medical Imaging
- Middle Aged
- Male
- Humans
- Ethylene Glycols
- Cognitive Dysfunction
- Carbolines
- Biomarkers
- Aniline Compounds